Trials / Completed
CompletedNCT00498797
E3-Hormone Refractory Prostrate Cancer Taxotere Combination
A Phase II, Double-blind, Placebo-controlled, Randomised Study to Assess the Efficacy and Safety of Docetaxel (Taxotere)/Prednisolone/ZD6474 vs Docetaxel/Prednisolone/Placebo in Patients With Hormone Refractory Prostrate Cancer (HRPC)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 86 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether treatment with Zactima (vandetanib) in combination with Docetaxel and Prednisolone is more effective than the standard Docetaxel and Prednisolone alone for prostate cancer, in patients with Hormone refractory prostate cancer who have not previously received chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zactima (vandetanib) | |
| DRUG | Docetaxel | |
| DRUG | Prednisolone |
Timeline
- Start date
- 2005-12-01
- Primary completion
- 2007-07-01
- Completion
- 2008-09-01
- First posted
- 2007-07-10
- Last updated
- 2016-10-07
- Results posted
- 2011-05-24
Locations
11 sites across 5 countries: Brazil, Germany, Hungary, South Africa, Sweden
Source: ClinicalTrials.gov record NCT00498797. Inclusion in this directory is not an endorsement.